Systematic review with meta-analysis: Mucosal healing is associated with improved long-term outcomes in Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue 3, 2016, Pages 317-333

  Shah, S C ^a   Colombel, J F ^a   Sands, B E ^a   Narula, N ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; MYCOPHENOLATE MOFETIL; NATALIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

CROHN DISEASE; CYTAPHERESIS; ENTERIC FEEDING; HEALING; HUMAN; INTESTINE ENDOSCOPY; INTESTINE MUCOSA; INTESTINE SURGERY; MUCOSAL HEALING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; GASTROINTESTINAL ENDOSCOPY; META ANALYSIS; PATHOLOGY; PROSPECTIVE STUDY; WOUND HEALING;

CROHN DISEASE; ENDOSCOPY, GASTROINTESTINAL; HUMANS; INTESTINAL MUCOSA; PROSPECTIVE STUDIES; REMISSION INDUCTION; WOUND HEALING;

EID: 84955349443     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13475     Document Type: Review

References (102)

1. Cosnes J, Cattan S, Blain A, et al,. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-50.
2. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A,. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011; 140: 1785-94.
3. De Cruz P, Kamm MA, Prideaux L, Allen PB, Moore G,. Mucosal healing in Crohn's disease: a systematic review. Inflamm Bowel Dis 2013; 19: 429-44.
4. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ,. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010; 105: 289-97.
5. Greenberg GR, Feagan BG, Martin F, et al,. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology 1996; 110: 45-51.
6. Landi B, Anh TN, Cortot A, et al,. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992; 102: 1647-53.
7. Mary JY, Modigliani R,. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989; 30: 983-9.
8. Modigliani R, Mary JY, Simon JF, et al,. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990; 98: 811-8.
9. Gollop JH, Phillips SF, Melton LJ 3rd, Zinsmeister AR,. Epidemiologic aspects of Crohn's disease: a population based study in Olmsted County, Minnesota, 1943-1982. Gut 1988; 29: 49-56.
10. Solberg IC, Vatn MH, Hoie O, et al,. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007; 5: 1430-8.
11. Loftus EV Jr, Schoenfeld P, Sandborn WJ,. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002; 16: 51-60.
12. Froslie KF, Jahnsen J, Moum BA, Vatn MH,. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-22.
13. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
14. Baert F, Moortgat L, Van Assche G, et al,. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010; 138: 463-8; quiz e10-1.
15. Schnitzler F, Fidder H, Ferrante M, et al,. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009; 15: 1295-301.
16. Rutgeerts P, Diamond RH, Bala M, et al,. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006; 63: 433-42; quiz 64.
17. Ananthakrishnan AN, Korzenik JR, Hur C,. Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis Inflamm Bowel Dis 2013; 19: 37-44.
18. Stang A,. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603-5.
19. Higgins JP, Altman DG, Gotzsche PC, et al,. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (Clin Res Ed) 2011; 343: d5928.
20. Athanasiou T, Al-Ruzzeh S, Kumar P, et al,. Off-pump myocardial revascularization is associated with less incidence of stroke in elderly patients. Ann Thorac Surg 2004; 77: 745-53.
21. Narula N, Al-Dabbagh R, Dhillon A, Sands BE, Marshall JK,. Anti-TNFalpha therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2014; 20: 1862-9.
22. Narula N, Charleton D, Marshall JK,. Meta-analysis: peri-operative anti-TNF alpha treatment and post-operative complications in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 37: 1057-64.
23. Cornish J, Tan E, Teare J, et al,. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 2007; 56: 830-7.
24. Savovic J, Weeks L, Sterne JA, et al,. Evaluation of the Cochrane Collaboration's tool for assessing the risk of bias in randomized trials: focus groups, online survey, proposed recommendations and their implementation. Syst Rev 2014; 3: 37.
25. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ (Clin Res Ed) 2003; 327: 557-60.
26. Barta Z, Toth L, Zeher M,. Pulse cyclophosphamide therapy for inflammatory bowel disease. World J Gastroenterol 2006; 12: 1278-80.
27. Beigel F, Deml M, Schnitzler F, et al,. Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies. PLoS ONE 2014; 9: e99293.
28. Beppu T, Ono Y, Matsui T, et al,. Mucosal healing of ileal lesions is associated with long-term clinical remission after infliximab maintenance treatment in patients with Crohn's disease. Dig Endosc 2015; 27: 73-81.
29. Berni Canani R, Terrin G, Borrelli O, et al,. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease. Dig Liver Dis 2006; 38: 381-7.
30. Bouguen G, Levesque BG, Pola S, Evans E, Sandborn WJ,. Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn's disease. Clin Gastroenterol Hepatol 2014; 12: 978-85.
31. Colombel JF, Reinisch W, Mantzaris GJ, et al,. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease-a SONIC post hoc analysis. Aliment Pharmacol Ther 2015; 41: 734-46.
32. D'Haens G, Baert F, van Assche G, et al,. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-7.
33. D'Haens G, Van Deventer S, Van Hogezand R, et al,. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999; 116: 1029-34.
34. Falvey JD, Hoskin T, Meijer B, et al,. Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission. Inflamm Bowel Dis 2015; 21: 824-31.
35. Hall B, Holleran G, Chin JL, et al,. A prospective 52 week mucosal healing assessment of small bowel Crohn's disease as detected by capsule endoscopy. J Crohns Colitis 2014; 8: 1601-9.
36. Hasselblatt P, Drognitz K, Potthoff K, et al,. Remission of refractory Crohn's disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantation. Aliment Pharmacol Ther 2012; 36: 725-35.
37. Kane SV, Horst S, Sandborn WJ, et al,. Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience. Inflamm Bowel Dis 2012; 18: 2203-8.
38. Molander P, Sipponen T, Kemppainen H, et al,. Achievement of deep remission during scheduled maintenance therapy with TNFalpha-blocking agents in IBD. J Crohns Colitis 2013; 7: 730-5.
39. Slonim AE, Grovit M, Bulone L,. Effect of exclusion diet with nutraceutical therapy in juvenile Crohn's disease. J Am Coll Nutr 2009; 28: 277-85.
40. Sorrentino D, Terrosu G, Paviotti A, et al,. Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn's disease: partial benefit by infliximab-a pilot study. Dig Dis Sci 2012; 57: 1341-8.
41. Tursi A, Elisei W, Brandimarte G, Giorgetti G, Penna A, Castrignano V,. Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice. Eur Rev Med Pharmacol Sci 2010; 14: 47-55.
42. Van Assche G, Herrmann KA, Louis E, et al,. Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease. J Crohns Colitis 2013; 7: 950-7.
43. Yamamoto T, Nakahigashi M, Umegae S, Kitagawa T, Matsumoto K,. Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflamm Bowel Dis 2005; 11: 580-8.
44. Yu L, Yang X, Xia L, et al,. Infliximab preferentially induces clinical remission and mucosal healing in short course Crohn's disease with luminal lesions through balancing abnormal immune response in gut mucosa. Mediators Inflamm 2015; 2015: 793764.
45. Zubin G, Peter L,. Predicting endoscopic crohn's disease activity before and after induction therapy in children: a comprehensive assessment of PCDAI, CRP, and fecal calprotectin. Inflamm Bowel Dis 2015; 21: 1386-91.
46. Allez M, Lemann M, Bonnet J, Cattan P, Jian R, Modigliani R,. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002; 97: 947-53.
47. Angelberger S, Schaeffeler E, Teml A, et al,. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflamm Bowel Dis 2013; 19: 590-8.
48. Mantzaris GJ, Christidou A, Sfakianakis M, et al,. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm Bowel Dis 2009; 15: 375-82.
49. Rismo R, Olsen T, Ciu G, et al,. The effect of adalimumab for induction of endoscopic healing and normalization of mucosal cytokine gene expression in Crohn's disease. Scand J Gastroenterol 2012; 47: 1200-10.
50. Tung J, Loftus EV Jr, Freese DK, et al,. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2006; 12: 1093-100.
51. Uhlen S, Belbouab R, Narebski K, et al,. Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study. Inflamm Bowel Dis 2006; 12: 1053-7.
52. Bortlik M, Duricova D, Malickova K, et al,. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J Crohns Colitis 2013; 7: 736-43.
53. Cezard JP, Nouaili N, Talbotec C, et al,. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric crohn disease. J Pediatr Gastroenterol Nutr 2003; 36: 632-6.
54. Ciccocioppo R, Bernardo ME, Sgarella A, et al,. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 2011; 60: 788-98.
55. Fukuchi T, Nakase H, Ubukata S, et al,. Therapeutic effect of intensive granulocyte and monocyte adsorption apheresis combined with thiopurines for steroid- and biologics-naive Japanese patients with early-diagnosed Crohn's disease. BMC Gastroenterol 2013; 13: 124.
56. Guidi L, Marzo M, Andrisani G, et al,. Faecal calprotectin assay after induction with anti-tumour necrosis factor alpha agents in inflammatory bowel disease: prediction of clinical response and mucosal healing at one year. Dig Liver Dis 2014; 46: 974-9.
57. Kiss LS, Szamosi T, Molnar T, et al,. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. Aliment Pharmacol Ther 2011; 34: 911-22.
58. Kiss LS, Szamosi T, Molnar T, et al,. Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary. Orv Hetil 2011; 152: 1433-42.
59. Lopez Palacios N, Mendoza JL, Taxonera C, Lana R, Fuentes Ferrer M, Diaz-Rubio M,. Adalimumab induction and maintenance therapy for Crohn's disease. An open-label study. Rev Esp Enferm Dig 2008; 100: 676-81.
60. Murakami Y, Matsui T, Hirai F, et al,. Efficacy of azathioprine in mild or moderate relapse in Crohn's disease: clinical and endoscopic evaluation. Dig Endosc 2010; 22: 25-32.
61. Olbjorn C, Nakstad B, Smastuen MC, Thiis-Evensen E, Vatn MH, Perminow G,. Early anti-TNF treatment in pediatric Crohn's disease. Predictors of clinical outcome in a population-based cohort of newly diagnosed patients. Scand J Gastroenterol 2014; 49: 1425-31.
62. Reiter MJ, Mann DE, Reiffel JE, Hahn E, Hartz V,. Significance and incidence of concordance of drug efficacy predictions by Holter monitoring and electrophysiological study in the ESVEM Trial. Electrophysiologic study versus electrocardiographic monitoring. Circulation 1995; 91: 1988-95.
63. Colombel JF, Rutgeerts PJ, Sandborn WJ, et al,. Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol 2014; 12: 414-22.e5.
64. Echarri A, Ollero V, Barreiro-de Acosta M, et al,. Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naive Crohn's disease: predictors of efficacy in clinical practice. Eur J Gastroenterol Hepatol 2015; 27: 430-5.
65. Fan R, Zhong J, Wang ZT, Li SY, Zhou J, Tang YH,. Evaluation of "top-down" treatment of early Crohn's disease by double balloon enteroscopy. World J Gastroenterol 2014; 20: 14479-87.
66. Geboes K, Rutgeerts P, Opdenakker G, et al,. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Curr Med Res Opin 2005; 21: 1741-54.
67. Hebuterne X, Lemann M, Bouhnik Y, et al,. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut 2013; 62: 201-8.
68. Li Y, Lopez R, Queener E, Shen B,. Adalimumab therapy in Crohn's disease of the ileal pouch. Inflamm Bowel Dis 2012; 18: 2232-9.
69. Lindberg A, Eberhardson M, Karlsson M, Karlen P,. Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease. BMC Gastroenterol 2010; 10: 73.
70. Reinisch W, Colombel JF, Sandborn WJ, et al,. Factors associated with short- and long-term outcomes of therapy for Crohn's disease. Clin Gastroenterol Hepatol 2015; 13: 539-47.e2.
71. Rutgeerts P, Van Assche G, Sandborn WJ, et al,. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012; 142: 1102-11.e2.
72. af Bjorkesten CG, Nieminen U, Sipponen T, Turunen U, Arkkila P, Farkkila M,. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scand J Gastroenterol 2013; 48: 543-51.
73. Cohen SA, Gold BD, Oliva S, et al,. Clinical and mucosal improvement with specific carbohydrate diet in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2014; 59: 516-21.
74. Czaja-Bulsa G, Gebala A, Korlatowicz-Bilar A,. Infliximab treatment time and the mucosal healing effect in pediatric patients with severe Crohn's disease-own experience. Przeglad Gastroenterologiczny 2012; 7: 87-93.
75. Dai C, Liu WX, Jiang M, Sun MJ,. Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy. PLoS ONE 2014; 9: e110797.
76. Grover Z, Muir R, Lewindon P,. Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in paediatric Crohn's disease. J Gastroenterol 2014; 49: 638-45.
77. Feagan BG, Lemann M, Befrits R, et al,. Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report. Inflamm Bowel Dis 2012; 18: 152-60.
78. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Farkkila M,. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008; 14: 40-6.
79. Sidler MA, Leach ST, Day AS,. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm Bowel Dis 2008; 14: 359-66.
80. Jones J, Loftus EV Jr, Panaccione R, et al,. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008; 6: 1218-24.
81. Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ,. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 707-12.
82. Mitselos IV, Christodoulou DK, Katsanos KH, Tsianos EV,. Role of wireless capsule endoscopy in the follow-up of inflammatory bowel disease. World J Gastrointest Endosc 2015; 7: 643-51.
83. Kopylov U, Seidman EG,. Role of capsule endoscopy in inflammatory bowel disease. World J Gastroenterol 2014; 20: 1155-64.
84. Park SK, Ye BD, Kim KO, et al,. Guidelines for video capsule endoscopy: emphasis on Crohn's disease. Clin Endosc 2015; 48: 128-35.
85. Efthymiou A, Viazis N, Mantzaris G, et al,. Does clinical response correlate with mucosal healing in patients with Crohn's disease of the small bowel? A prospective, case-series study using wireless capsule endoscopy. Inflamm Bowel Dis 2008; 14: 1542-7.
86. Dubcenco E, Jeejeebhoy KN, Petroniene R, et al,. Capsule endoscopy findings in patients with established and suspected small-bowel Crohn's disease: correlation with radiologic, endoscopic, and histologic findings. Gastrointest Endosc 2005; 62: 538-44.
87. Siddiki HA, Fidler JL, Fletcher JG, et al,. Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. Am J Roentgenol 2009; 193: 113-21.
88. Wold PB, Fletcher JG, Johnson CD, Sandborn WJ,. Assessment of small bowel Crohn disease: noninvasive peroral CT enterography compared with other imaging methods and endoscopy-feasibility study. Radiology 2003; 229: 275-81.
89. Bruining DH, Loftus EV Jr, Ehman EC, et al,. Computed tomography enterography detects intestinal wall changes and effects of treatment in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011; 9: 679-83.e1.
90. Rimola J, Ordas I, Rodriguez S, et al,. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis 2011; 17: 1759-68.
91. van Hogezand RA, Witte AM, Veenendaal RA, Wagtmans MJ, Lamers CB,. Proximal Crohn's disease: review of the clinicopathologic features and therapy. Inflamm Bowel Dis 2001; 7: 328-37.
92. Reynolds HL Jr, Stellato TA,. Crohn's disease of the foregut. Surg Clin North Am 2001; 81: 117-35, viii.
93. Theodoropoulou A, Koutroubakis IE, Kouroumalis EA,. Treatment of oesophageal Crohn's disease with infliximab. Eur J Gastroenterol Hepatol 2004; 16: 431-2.
94. Ferrante M, Colombel JF, Sandborn WJ, et al,. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology 2013; 145: 978-86.e5.
95. Khanna R, Bouguen G, Feagan BG, et al,. A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design. Inflamm Bowel Dis 2014; 20: 1850-61.
96. Dave M, Loftus EV Jr,. Mucosal healing in inflammatory bowel disease-a true paradigm of success? Gastroenterol Hepatol 2012; 8: 29-38.
97. Louis E, Mary JY, Vernier-Massouille G, et al,. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142: 63-70.e5; quiz e31.
98. Lemann M, Mary JY, Colombel JF, et al,. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005; 128: 1812-8.
99. Colombel JF, Sandborn WJ, Reinisch W, et al,. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
100. Targan SR, Hanauer SB, van Deventer SJ, et al,. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
101. Travis S, Feagan BG, Rutgeerts P, van Deventer S,. The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapy. J Crohns Colitis 2012; 6 (Suppl. 2): S250-9.
102. Reinisch W, Van Assche G, Befrits R, et al,. Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus. J Crohns Colitis 2012; 6: 248-58.